Novus Biologicals Launches new Exon Specific HIF-1 Alpha Antibodies

Novus Biologicals just released four new HIF-1 alpha antibodies, specific to various HIF exons (exon 9: NBP1-47178, exon 10: NBP1-47179, exon 12: NBP1-47180, exon 13: NBP1-47181). These new exon specific HIF-1 Alpha antibodies have been positively validated for use in Western blot and cross-react with human.  

Novus' new HIF-1 alpha [exon 9] antibody recognizes exon 9 of HIF-1 alpha, which contains the 5' end of the ODDD (Oxygen Dependent Degradation Domain) region, whereas the exon 10 antibody recognizes exon 10 which contains the 3' end of the ODDD region. Another new HIF-1 alpha antibody, catalog number NBP1-47180, recognizes exon 12 which contains the 3' end of the N-terminal TAD (Transactivational Domain) and the 5' end of the ID (Inhibitory Domain). There are reports of isoforms that lack either exon 12, or exon 11 and 12. Lastly, catalog number NBP1-47181 recognizes exon 13 which contains the central area of the ID region.

These new exon specific HIF antibodies are Investigative Grade and are therefore being offered at a discounted price of $195. Sample sizes are also available, allowing researchers to test a small amount of antibody prior to purchasing the full size vial.  Novus' Investigative Grade antibodies are made against targets that are not commercially available and for which there are no expression data in common cell lines and/or tissues. These antibodies are affinity purified using their peptide immunogen and are known to give low background staining in Western blot, however, no additional claims are made for their ability to recognize native protein in any application.


For more information on these new exon specific HIF-1 alpha antibodies or to inquire about product collaborations, please contact the Novus Product Development Team by calling 303-730-1950 or via e-mail at

Release Date: 
Tuesday, September 7, 2010 - 06:00